However, more data are needed to assess whether gastric emptying will be more affected by GLP1RAs in patients with pre-exposure gastric motility disorders, and whether it might result in clinically significant PK changes
Expect modest, gradual improvement thats measurable on instrumental skin assessment but subtle visually
I have no idea if BPC-157 is safe, but it would be nice to know my patients are actually receiving it from a licensed pharmacy
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying, causing common gastrointestinal side effects including nausea, bloating, and altered bowel habits
The recommended dose is 480 mg twice daily
No wonder early commentators have lauded triple-agonists as a potential home run for obesity treatment